Description: Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name. The company was incorporated in 2020 and is headquartered in Stockholm, Sweden.
Home Page: vimian.com
Riddargatan 19
Stockholm,
11457
Sweden
Phone:
46 7 36 26 88 86
Officers
| Name | Title |
|---|---|
| Mr. Fredrik Ullman | Chief Exec. Officer |
| Mr. Carl-Johan Zetterberg Boudrie | Chief Financial Officer |
| Ms. Maria Dahllof Tullberg | Head of IR, Communications & Sustainability |
| Mr. Carl-Johan Ehn | Gen. Counsel |
| Mr. Magnus Kjellberg | Chief Exec. Officer of Nextmune |
| Mr. Martin Bengtson | Head of M&A |
| Mr. Stefano Santarelli | Chief Exec. Officer of Indical Bioscience |
| Mr. Guy C. Sporri | Co-Chief Exec. Officer of Movora |
| Mr. Alireza Tajbakhsh | Head & CEO of VetFamily |
| Colleen Flesher | Co-Chief Exec. Officer of Movora |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 54 |
| Price-to-Book MRQ: | 3.2866 |
| Price-to-Sales TTM: | 46.9243 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 885 |